We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Joint Postmarket Study Possible To Allay Broader Safety Concerns
Joint Postmarket Study Possible To Allay Broader Safety Concerns
May 2, 2012
The European Medicines Agency (EMA) could require multiple drugmakers to conduct a joint post-authorization safety study (PASS) if concerns about the risk of a particular compound apply to more than one drug, according to the agency.